香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 關於子公司重大訴訟的進展公告 茲提述國聯民生證券股份有限公司（「公司」、「本公司」）日期為2022年8月5日、2022年 9月1日及2025年8月26日的公告，內容有關（其中包括）本公司全資子公司國聯民生證 券承銷保薦有限公司（「國聯民生承銷保薦」，曾用名：華英證券有限責任公司）涉及 重大訴訟。 近日，國聯民生承銷保薦收到山東省高級人民法院（「山東高院」）送達的《受理案件 通知書》，現將相關信息公告如下： 一、訴訟的基本情况 一審原告李立群等1,618名投資者起訴山東龍力生物科技股份有限公司、程少 博等12名自然人、國聯民生承銷保薦、立信會計師事務所（特殊普通合夥）等15 名一審被告的證券虛假陳述責任糾紛普通代表人訴訟的基本情況及一審判決 結果詳見公司日期分別為2022年8月5日、2022年9月1日及2025年8月26日公告。 1 二、訴 ...

根据该批复，中国证监会同意公司向专业投资者公开发行面值总额不超过30亿元永续次级债券的注册申 请。该批复自同意注册之日起24个月内有效，公司在注册有效期内可以分期发行永续次级债券。 格隆汇1月28日丨国联民生(01456.HK)公告，近日，国联民生证券股份有限公司收到中国证券监督管理 委员会出具的《关于同意国联民生证券股份有限公司向专业投资者公开发行永续次级债券注册的批复》 (证监许可﹝2026﹞125号)。 ...

Core Viewpoint - The company has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue perpetual subordinated bonds with a total face value of up to 3 billion yuan [1] Group 1: Regulatory Approval - The CSRC issued a notice approving the company's application for the public issuance of perpetual subordinated bonds [1] - The approval is valid for 24 months from the date of issuance, allowing the company to issue the bonds in tranches during this period [1] Group 2: Financial Details - The total face value of the bonds to be issued is capped at 3 billion yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：01456） （於中華人民共和國成立的股份有限公司） 海外監管公告 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條作出。 如下公告已於上海證券交易所網站刊發，僅供參閱。 特此公告。 承董事會命 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 國聯民生證券股份有限公司 董事長 顧偉 中國江蘇省無錫市 2026年1月28日 截至本公告日期，本公司執行董事為葛小波先生；本公司非執行董事為顧偉先生、 周衛平先生、吳衛華先生及楊振興先生；本公司職工董事為陳興君先生；及本公司 獨立非執行董事為高偉先生、郭春明先生及徐慧敏女士。 证券代码：601456 证券简称：国联民生 公告编号：2026-003 号 国联民生证券股份有限公司 关于向专业投资者公开发行永续次级债券 获得中国证监会注册批复的公告 近日， ...

Group 1 - The global biotech and pharmaceutical investment and financing activities are expected to rebound significantly in 2025, driven by the robust development of innovative drug technology platforms, leading to a comprehensive recovery in the CXO industry and sustained industry prosperity into 2026 [1] - The Chinese CRO market is projected to return to a growth trajectory in 2025, with a notable 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic innovative drug market [1] - The demand side globally is showing a strong rebound, establishing a solid foundation for growth, with biotech financing reaching a historical high in Q4 2025 and multinational pharmaceutical companies experiencing a recovery in demand [1] Group 2 - WuXi AppTec (药明康德) is expected to report impressive performance in 2025, with adjusted net profit increasing by 41.3%, driven by the TIDES business, which has seen revenue growth exceeding 90% [2] - WuXi Biologics has reached a record high of 945 projects, with a 30% growth in dual monoclonal and ADC projects, indicating a strong pipeline for future commercialization [2] - WuXi AppTec's subsidiary, WuXi STA, is focusing on the ADC/XDC sector, with revenue growth exceeding 40% in 2025 and an increase in global market share to over 24% [2] Group 3 - The Chinese clinical CRO market is at a clear turning point, with Tigermed (泰格医药) benefiting from the industry recovery, as order prices stabilize and the domestic clinical pipeline grows alongside improved financing conditions [3] Group 4 - Global CDMO giants are accelerating expansion, with optimistic performance guidance; Fujifilm is expected to secure $8 billion in new orders in 2025, reflecting strong demand for large molecule CDMO services [4] - Charles River anticipates an improvement in order trends starting in H2 2025, with a forecast for revenue growth in its safety assessment business by H2 2026, serving as an early indicator of recovery in the CXO industry [4] Group 5 - Investment recommendations include focusing on leading clinical CRO platforms like Tigermed and niche leaders such as Pruis, as well as front-end CRO companies with shorter order fulfillment cycles and greater marginal elasticity [5] - In the CDMO sector, attention is advised on leading companies in the peptide supply chain, ADC beneficiaries, and those with forward-looking layouts in small nucleic acids, as well as companies with significant potential for marginal traction from large products [5]

Core Viewpoint - Aofei Data has decided to terminate its plan for a private placement of A-shares originally intended to raise 1.695 billion yuan, citing business development and strategic planning considerations [1][2]. Group 1: Termination of Private Placement - The private placement was intended to fund the "New Generation Cloud Computing and Artificial Intelligence Industrial Park" project, which aimed to enhance the company's IDC infrastructure in North China [2]. - The termination of the private placement was officially confirmed by the Shenzhen Stock Exchange on January 27 [1]. - Aofei Data stated that the decision would not significantly impact its operations or harm the interests of shareholders, particularly minority shareholders [2]. Group 2: Management Changes - Aofei Data's former General Manager, Huang Zhanpeng, resigned from his positions due to personal family reasons and held 124,100 shares, representing 0.01% of the total share capital [1]. Group 3: Financial Performance - Despite the termination of the private placement, Aofei Data reported strong financial performance for the first three quarters of 2025, with revenue reaching 1.824 billion yuan, a year-on-year increase of 15.33% [5]. - The net profit attributable to shareholders was 145 million yuan, up 37.29%, and EBITDA was 827 million yuan, reflecting a 38.77% increase [5]. - The company's IDC services generated approximately 1.387 billion yuan in revenue, a 42.22% increase, driven by improved data center deployment rates and energy management [5]. Group 4: Capital Structure and Financing - Since its listing in 2018, Aofei Data has raised a total of 2.637 billion yuan through direct financing, with cash dividends amounting to only 113 million yuan [5]. - The company's asset-liability ratio was reported at 75.83% as of the end of the third quarter of 2025, indicating a high level of financial leverage [5].

Core Viewpoint - Aofei Data (300738) has decided to terminate its plan to issue A-shares to specific investors for the year 2025, which was originally intended to raise 1.695 billion yuan [1][2] Group 1: Termination of Fundraising - The termination of the fundraising plan was based on the company's actual business development, future strategic planning, and project progress after careful consideration and communication with relevant parties [2] - The company emphasized that this decision will not have a significant impact on its business operations or harm the interests of shareholders, especially minority shareholders [2] Group 2: Management Changes - On the same day, Aofei Data announced the resignation of its former general manager, Huang Zhanpeng, due to personal family reasons, and he will no longer hold any position in the company [1] Group 3: Financial Performance - Despite the termination of the fundraising, Aofei Data reported strong financial performance for the first three quarters of 2025, with revenue reaching 1.824 billion yuan, a year-on-year increase of 15.33%, and a net profit attributable to shareholders of 145 million yuan, up 37.29% [4] - The company's EBITDA was 827 million yuan, reflecting a 38.77% increase, and the gross profit margin improved significantly by 5.29 percentage points to 34.99% compared to the same period in 2024 [4] Group 4: IDC Business Growth - The IDC services, as the core revenue source, generated approximately 1.387 billion yuan, a year-on-year increase of 42.22%, mainly benefiting from improved data center deployment rates and energy management optimization [5] - As of the end of September 2025, the total number of operational cabinets exceeded 57,000, representing a 33% increase compared to the end of 2024 [5] Group 5: Financial Structure - Aofei Data has raised a total of 2.637 billion yuan through direct financing since its listing eight years ago, with cumulative cash dividends amounting to only 113 million yuan [4] - The company's asset-liability ratio was high at 75.83% as of the end of the third quarter of 2025, leading to an increase in financial expenses [6]

中国经济网北京1月28日讯 阳光诺和(688621.SH)昨晚披露了关于终止发行股份及可转换公司债券购买资 产并募集配套资金暨关联交易事项并撤回申请文件的公告。 本次交易标的公司朗研生命为上市公司控股股东、实际控制人利虔控制的其他企业，根据上交所《科创 板股票上市规则》的规定，本次发行股份及可转换公司债券购买资产事项构成关联交易。 阳光诺和在昨晚的公告中表示，自公司筹划并首次公告本次交易以来，公司严格按照相关法律法规及规 范性文件要求，积极组织交易各相关方推进本次重组工作。鉴于市场环境变化等因素，为切实维护公司 及全体股东利益，经审慎研究，董事会同意公司终止本次重组事项，撤回本次重组相关申请文件。 阳光诺和2025年11月20日披露的发行股份及可转换公司债券购买资产并募集配套资金暨关联交易报告书 (申报稿) 显示，本次交易的独立财务顾问是国联民生（601456）证券承销保荐有限公司。本次交易方案 包括发行股份及可转换公司债券购买资产和发行股份募集配套资金两部分：上市公司拟向利虔、朗颐投 资等38名朗研生命全体股东以发行股份及可转换公司债券方式购买其所持有的朗研生命100%股权；上 市公司拟向不超过35名特定对 ...

近日，国联民生证券股份有限公司（以下简称"公司"）收到中国证券监督管理委员会（以下简称"中国 证监会"）出具的《关于同意国联民生证券股份有限公司向专业投资者公开发行公司债券注册的批复》 （证监许可﹝2026﹞122号），公司控股子公司民生证券股份有限公司（以下简称"民生证券"）收到中 国证监会出具的《关于同意民生证券股份有限公司向专业投资者公开发行公司债券注册的批复》（证监 许可﹝2026﹞131号）。 登录新浪财经APP 搜索【信披】查看更多考评等级 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 证券代码：601456 证券简称：国联民生 公告编号：2026-002号 国联民生证券股份有限公司关于公司及控股子公司向专业投资者公开发行公司债券获得中国证监会注册 批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据上述批复，中国证监会同意公司向专业投资者公开发行面值总额不超过180亿元公司债券的注册申 请，同意民生证券向专业投资者公开发行面值总额不超过80亿元公司债券的注册申请。上述批复自 ...

公司公告汇总 国联民生证券股份有限公司及控股子公司民生证券收到中国证监会批复，同意公司向专业投资者公开发 行面值总额不超过180亿元公司债券的注册申请，同意民生证券公开发行面值总额不超过80亿元公司债 券的注册申请。批复自同意注册之日起24个月内有效，可在注册有效期内分期发行。公司将按要求办理 发行事宜并履行信息披露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月27日收盘，国联民生(601456)报收于9.82元，下跌1.31%，换手率0.89%，成交量39.08万 手，成交额3.83亿元。 当日关注点 交易信息汇总资金流向 1月27日主力资金净流出2302.11万元，占总成交额6.0%；游资资金净流入2020.0万元，占总成交额 5.27%；散户资金净流入282.11万元，占总成交额0.74%。 来自交易信息汇总：1月27日主力资金净流出2302.11万元，占总成交额6.0%。 来自公司公告汇总：国联民生及控股子公司民生证券获证监会批复，同意注册合计不超过180亿元 公司债券发行申请。 ...